Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short-Term Debt issuances (2018 - 2025)

Amphastar Pharmaceuticals (AMPH) has 7 years of Short-Term Debt issuances data on record, last reported at $273000.0 in Q4 2025.

  • For Q4 2025, Short-Term Debt issuances fell 94.39% year-over-year to $273000.0; the TTM value through Dec 2025 reached $6.2 million, down 66.28%, while the annual FY2025 figure was $6.2 million, 66.28% down from the prior year.
  • Short-Term Debt issuances reached $273000.0 in Q4 2025 per AMPH's latest filing, up from $172000.0 in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $500.0 million in Q2 2023 and bottomed at -$25000.0 in Q2 2024.
  • Average Short-Term Debt issuances over 3 years is $58.3 million, with a median of $4.1 million recorded in 2024.
  • Peak YoY movement for Short-Term Debt issuances: tumbled 100.0% in 2024, then skyrocketed 16616.0% in 2025.
  • A 3-year view of Short-Term Debt issuances shows it stood at $500.0 million in 2023, then crashed by 99.03% to $4.9 million in 2024, then tumbled by 94.39% to $273000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Short-Term Debt issuances were $273000.0 in Q4 2025, $172000.0 in Q3 2025, and $4.1 million in Q2 2025.